The p53-MDM2/MDMX axis - A chemotype perspective

被引：58
|
作者：
Khoury, Kareem [1 ]
Popowicz, Grzegorz M. [2 ]
Holak, Tad A. [2 ]
Doemling, Alexander [1 ]
机构：
[1] Univ Pittsburgh, Dept Pharmaceut Sci, Drug Discovery Inst, Pittsburgh, PA 15260 USA
[2] Max Planck Inst Biochem, D-8000 Munich, Germany
来源：
MEDCHEMCOMM | 2011年 / 2卷 / 04期
关键词：
PROTEIN-PROTEIN INTERACTION; SUPPRESSOR TRANSACTIVATION DOMAIN; SMALL-MOLECULE ANTAGONISTS; STRUCTURE-BASED DESIGN; WILD-TYPE P53; MDM2; INHIBITORS; CANCER-THERAPY; IN-VIVO; IDENTIFY DISRUPTORS; HDM2; ANTAGONISTS;
D O I：
10.1039/c0md00248h
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The protein-protein interaction (PPI) of the tumor suppressor p53 and its negative regulator MDM2 consists of the most intense studied PPI with a group of small molecular weight antagonists described and many more disclosed in patent literature. Due to the A-level structural insight into p53 interaction with MDM2 there is a reasonable understanding of the requirements of the molecules to bind. In contrast and despite the very close homology and 3-D similarity no potent MDMX antagonist has been disclosed up to date. The current review summarizes the different disclosed chemotypes for MDM2 including a discussion of the cocrystal structures. Structures and approaches to reconstitute functional p53 from mutated p53 are presented. Finally new screening methods and recent biotech deals based on p53 are discussed.
引用
收藏
页码：246 / 260
页数：15
相关论文
共 50 条
  • [21] Oscillations by the p53-Mdm2 feedback loop
    Lahav, Galit
    CELLULAR OSCILLATORY MECHANISMS, 2008, 641 : 28 - 38
  • [22] The p53-Mdm2 module and the ubiquitin system
    Michael, D
    Oren, M
    SEMINARS IN CANCER BIOLOGY, 2003, 13 (01) : 49 - 58
  • [23] Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions
    Barakat, Khaled
    Mane, Jonathan
    Friesen, Douglas
    Tuszynski, Jack
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2010, 28 (06): : 555 - 568
  • [24] Controlling the Mdm2-Mdmx-p53 Circuit
    Waning, David L.
    Lehman, Jason A.
    Batuello, Christopher N.
    Mayo, Lindsey D.
    PHARMACEUTICALS, 2010, 3 (05): : 1576 - 1593
  • [25] Inhibition of p53-Mdm2 Interaction by Ellagitannins
    Tatsuda, D.
    Umezawa, Y.
    Iijima, M.
    Momose, I.
    Nomoto, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 66 - 66
  • [26] CHOP regulates the p53-MDM2 axis and is required for neuronal survival after seizures
    Engel, Tobias
    Sanz-Rodgriguez, Amaya
    Jimenez-Mateos, Eva M.
    Concannon, Caoimhin G.
    Jimenez-Pacheco, Alba
    Moran, Catherine
    Mesuret, Guillaume
    Petit, Emilie
    Delanty, Norman
    Farrell, Michael A.
    O'Brien, Donncha F.
    Prehn, Jochen H. M.
    Lucas, Jose J.
    Henshall, David C.
    BRAIN, 2013, 136 : 577 - 592
  • [27] BIOL 131-Genetic selection based search for small molecule inhibitors of p53-MDM2 and p53-MDMX interactions in cancer
    Datta, Shreya
    Bucks, Megan
    Lim, Pei Xim
    Savinov, Sergey N.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2008, 236
  • [28] α-Helix-Mimicking Sulfono-γ-AApeptide Inhibitors for p53-MDM2/MDMX Protein-Protein Interactions
    Sang, Peng
    Shi, Yan
    Lu, Junhao
    Chen, Lihong
    Yang, Leixiang
    Borcherds, Wade
    Abdulkadir, Sami
    Li, Qi
    Daughdrill, Gary
    Chen, Jiandong
    Cai, Jianfeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (03) : 975 - 986
  • [29] Structure-based discovery of novel ?-aminoketone derivatives as dual p53-MDM2/MDMX inhibitors for the treatment of cancer
    Luo, Hui-juan
    Si, Dong-juan
    Sun, Xin-jie
    Wang, Meng-yun
    Yang, Yao-bin
    Wang, Bo
    Wen, Hong-mei
    Li, Wei
    Liu, Jian
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 252
  • [30] D-Amino acid mutation of PMI as potent dual peptide inhibitors of p53-MDM2/MDMX interactions
    Li, Xiang
    Liu, Chao
    Chen, Si
    Hu, Honggang
    Su, Jiacan
    Zou, Yan
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (20) : 4678 - 4681
12345